insights_auto
Kodėl „4142“ sumažėjo 6,62%?
Įsigilintichevron_right
4142:TPE
Adimmune Corp
14,80 TWD
arrow_downward
−6,62%(−1,05) 1 D.
11-20, 13:30:09 GMT+8 · TWD
search
Visi simboliai
| Simbolis | Kaina | Keisti | Pokytis, % |
|---|
insights_autoGeneruojamos svarbiausios „4142“ įžvalgos...
Atidaryti
15,75 TWD
Aukšta
15,75 TWD
Žema
14,80 TWD
Rinkos kapitalizacija
6,36 mlrd.
Vid. kiekis
1,13 mln.
Apimtis
1,63 mln.
P/E santykis
85,76
52 sav. aukšta
21,50 TWD
52 sav. žema
14,80 TWD
Pajamos iš vienos akcijos
0,17 TWD
Neapmokėtos akcijos
235,29 mln.
Darbuotojų skaičius
564
Atidaryti
15,75 TWD
Aukšta
15,75 TWD
Žema
14,80 TWD
Rinkos kapitalizacija
6,36 mlrd.
Vid. kiekis
1,13 mln.
Apimtis
1,63 mln.
P/E santykis
85,76
52 sav. aukšta
21,50 TWD
52 sav. žema
14,80 TWD
Pajamos iš vienos akcijos
0,17 TWD
Neapmokėtos akcijos
235,29 mln.
Darbuotojų skaičius
564
Naujienų istorijos
Iš žiniatinklio šaltinių ir naujienų partnerių
Beinsure
·
prieš 2 valandas
S&P 500 forecast for 2027: Wall Street expects a rebound after an 11.6% drop fueled by AI fears
Trefis
·
prieš 4 valandas
25 S&P 500 Stocks Just Made New 52-Week Lows
Los Angeles Times
·
prieš 19 valandų
S&P 500 falls 10% from record, entering correction as AI trade unravels
Yahoo Finance
·
prieš 15 valandų
Wall St ends sharply lower on AI selloff, S&P 500, Dow in correction
Profilis
Adimmune Corporation is a Taiwanese pharmaceutical company engaged in the research, development, manufacturing, and sales of medicines and vaccines for both humans and animals. Its products are supplied to both local and international markets.
Founded in 1965 and headquartered in Tanzi District, Taichung, it has a market cap of US$230 million, 564 employees and annual sales of $106 million as of 2026.
Adimmune continues to seek expansion its role in the regional pharmaceutical and vaccine industry through international collaborations.
In January 2021, Adimmune Corporation announced a partnership with Sam Chun Dang Pharm to jointly develop an injectable medication used to treat macular disease.
In July 2021, the company announced that its first overseas manufacturing site will be situated in the Special Economic Zone in East Java, Indonesia, aiming to launch clinical trials for its COVID-19 vaccine in Indonesia early 2022.
In August 2021, Adimmune Corporation signed a memorandum of understanding with Becton, Dickinson and Company to strengthen its international pharmaceutical collaboration. Wikipedia
Apie „Adimmune Corp“
Generalinis direktorius-
Darbuotojai564
Įkurta1965
Pagrindinė būstinė-
SektoriusHealth Care
Pramonės sritis-
Svetainėadimmune.com.tw